Orgun Doruk, Ellervik Christina, Poulsen Henrik Enghusen, Nordestgaard Børge Grønne, Gogenur Ismail, Nordestgaard Ask Tybjærg
Center for Surgical Science, Department of Surgery, Zealand University Hospital Køge, Køge, Denmark.
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
BJS Open. 2025 Jul 1;9(4). doi: 10.1093/bjsopen/zraf087.
Although overt systemic inflammation immediately before gastrointestinal surgery has been associated with postoperative complications and mortality, it remains unclear whether baseline low-grade inflammation measured by high-sensitivity C-reactive protein (hs-CRP) in a non-surgery-related state is associated with the same outcomes.
This study included a subset of individuals from the Copenhagen General Population Study (CGPS) who underwent any type of gastrointestinal surgery between 2003 and 2015 after enrolment in the CGPS. Exposures were baseline hs-CRP levels (used in observational analyses) and two genetic variants that affect hs-CRP levels, namely interleukin 6 receptor (IL6R) rs4537545 and CRP rs1130864 (used in Mendelian randomization analyses), all of which were tested routinely at CGPS enrolment. Primary outcomes were 30-day complications and 90-day and 5-year mortality after the index surgery. Associations between exposures and outcomes were assessed using multivariable Cox regression models.
Of the 107 536 individuals in the CGPS, 12 803 were included in the present study. Of these individuals, 1236 (9.7%) experienced 30-day complications, 865 (6.8%) died within 90 days, and 2789 (21.8%) died within 5 years. Adjusted hazard ratios for the highest hs-CRP quartile (hs-CRP ≥ 2.73 mg/l) versus the lowest quartile (hs-CRP < 1.04 mg/l) were 1.19 (95% confidence interval (c.i.) 1.02 to 1.40; P = 0.029) for 30-day complications, 1.29 (95% c.i. 1.07 to 1.57; P = 0.009) for 90-day mortality, and 1.17 (95% c.i. 1.06 to 1.31; P = 0.003) for 5-year mortality. Sensitivity analyses restricted to those with hs-CRP measurements within 1 year before surgery had larger point estimates. Genetically predicted elevations in hs-CRP were not associated with any outcomes.
Baseline hs-CRP levels ≥ 2.73 mg/l, consistent with chronic low-grade systemic inflammation, were associated with higher risk of 30-day complications, 90-day mortality, and 5-year mortality after gastrointestinal surgery.
尽管胃肠道手术前明显的全身炎症与术后并发症和死亡率相关,但在非手术相关状态下通过高敏C反应蛋白(hs-CRP)测量的基线低度炎症是否与相同结局相关仍不清楚。
本研究纳入了哥本哈根普通人群研究(CGPS)中的一部分个体,这些个体在2003年至2015年期间入选CGPS后接受了任何类型的胃肠道手术。暴露因素为基线hs-CRP水平(用于观察性分析)以及两个影响hs-CRP水平的基因变异,即白细胞介素6受体(IL6R)rs4537545和CRP rs1130864(用于孟德尔随机化分析),所有这些均在CGPS入选时常规检测。主要结局为初次手术后30天并发症、90天和5年死亡率。使用多变量Cox回归模型评估暴露因素与结局之间的关联。
在CGPS的107536名个体中,12803名被纳入本研究。在这些个体中,1236名(9.7%)发生了30天并发症,865名(6.8%)在90天内死亡,2789名(21.8%)在5年内死亡。hs-CRP最高四分位数(hs-CRP≥2.73mg/l)与最低四分位数(hs-CRP<1.04mg/l)相比,30天并发症的调整后风险比为1.19(95%置信区间(c.i.)1.02至1.40;P=0.029),90天死亡率为1.29(95%c.i.1.07至1.57;P=0.009),5年死亡率为1.17(95%c.i.1.06至1.31;P=0.003)。仅限于手术前1年内进行hs-CRP测量的敏感性分析得到的点估计值更大。基因预测的hs-CRP升高与任何结局均无关联。
基线hs-CRP水平≥2.73mg/l,与慢性低度全身炎症一致,与胃肠道手术后30天并发症、90天死亡率和5年死亡率的较高风险相关。